Zevra Therapeutics, Inc.ZVRANASDAQ
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank100
3Y CAGR+323.0%
5Y CAGR+66.7%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+323.0%/yr
vs -9.0%/yr prior
5Y CAGR
+66.7%/yr
Recent acceleration
Acceleration
+332.0pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
12.9x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $16.80M | +126.5% |
| 2024 | $7.42M | +151.9% |
| 2023 | $2.94M | +1226.6% |
| 2022 | $222000.00 | -89.2% |
| 2021 | $2.06M | +57.8% |
| 2020 | $1.30M | -55.7% |
| 2019 | $2.94M | +809.0% |
| 2018 | $324000.00 | -3.6% |
| 2017 | $336000.00 | +92.0% |
| 2016 | $175000.00 | - |